ClinVar Miner

Submissions for variant NM_000441.2(SLC26A4):c.716T>A (p.Val239Asp)

dbSNP: rs111033256
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 27
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000169244 SCV000220521 likely pathogenic Pendred syndrome 2014-07-18 criteria provided, single submitter literature only
Eurofins Ntd Llc (ga) RCV000724118 SCV000331645 pathogenic not provided 2016-07-15 criteria provided, single submitter clinical testing
Invitae RCV000724118 SCV000947211 pathogenic not provided 2024-01-21 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 239 of the SLC26A4 protein (p.Val239Asp). This variant is present in population databases (rs111033256, gnomAD 0.2%). This missense change has been observed in individuals with SLC26A4-related conditions (PMID: 12974744, 16460646, 23770805, 25394566). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 43566). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC26A4 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects SLC26A4 function (PMID: 16460646, 22116360). For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000169244 SCV001337950 pathogenic Pendred syndrome 2020-01-14 criteria provided, single submitter clinical testing Variant summary: SLC26A4 c.716T>A (p.Val239Asp) results in a non-conservative amino acid change located in the SLC26A/SulP transporter domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0002 in 251468 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in SLC26A4 causing Pendred syndrome (0.0002 vs 0.0035). c.716T>A has been reported in the literature in numerous individuals affected with Pendred syndrome (eg. Khan_2013, Dossena_2011). These data indicate that the variant is very likely to be associated with disease. Experimental evidence reports the variant to lead to improper intracellular localization and retainment in the endoplasmic retuclum, and impaired protein function (Walsh_2006, Dossena_2011). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
GeneDx RCV000724118 SCV001766345 pathogenic not provided 2023-10-12 criteria provided, single submitter clinical testing Common variant accounting for approximately 30% of the mutant alleles of SLC26A4; suggested to be a founder variant in the Pakistani population (Anwar et al., 2009); Published functional studies demonstrate that this variant reduces anion transport activity, affects protein localization and overall severely impairs normal protein function (Park et al., 2003; Dossena et al., 2011); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27771369, 23965030, 33879512, 25394566, 16460646, 12676893, 12974744, 23336812, 30077349, 23504402, 31389194, 30303587, 23770805, 31599023, 32417962, 34171171, 33231815, 32747562, 33199029, 22116360, 19287372)
Revvity Omics, Revvity RCV000724118 SCV002020678 pathogenic not provided 2023-06-16 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV000169244 SCV002026675 pathogenic Pendred syndrome 2021-09-05 criteria provided, single submitter clinical testing
3billion RCV001004629 SCV002058856 pathogenic Autosomal recessive nonsyndromic hearing loss 4 2022-01-03 criteria provided, single submitter clinical testing Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000043566, PMID:12676893, PS1_S). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 2 similarly affected unrelated individuals(PMID: 12676893, 23504402, 30303587, PM3_S). Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID: 31599023, PS3_S). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.935, 3CNET: 0.981, PP3_P). A missense variant is a common mechanism associated with Deafness (PP2_P). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000203, PM2_M).Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline.
King Laboratory, University of Washington RCV001004629 SCV002059883 pathogenic Autosomal recessive nonsyndromic hearing loss 4 2020-08-01 criteria provided, single submitter research SLC26A4 c.716T>A, p.V239D has been shown to decrease SLC26A4 ion transport activity (PMID: 22116360). The variant is homozygous in 10 Palestinian children from a single kindred with pre-lingual hearing loss (Abu Rayyan 2020). It is present in 1 of 1300 Palestinian controls, as a heterozygote, and present in 51/251468 alleles on gnomAD, all heterozygotes.
Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center RCV001814026 SCV002061796 pathogenic Autosomal recessive nonsyndromic hearing loss 4; Pendred syndrome 2021-12-28 criteria provided, single submitter clinical testing PS3, PM3_strong, PP1, PP3, PM1
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute RCV001004629 SCV002557167 pathogenic Autosomal recessive nonsyndromic hearing loss 4 2020-05-25 criteria provided, single submitter clinical testing Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss-of-function is a known mechanism of disease for this gene. (N) 0106 - This gene is known to be associated with autosomal recessive disease. (N) 0200 - Variant is predicted to result in a missense amino acid change from valine to aspartic acid (exon 6). (N) 0252 - Variant is homozygous. (N) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (51 heterozygotes, 0 homozygotes). (P) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (P) 0600 - Variant is located in an annotated domain or motif (sulfate permease family domain; PDB). (N) 0705 - No comparable variants have previous evidence for pathogenicity. (N) 0801 - Strong previous evidence of pathogenicity in unrelated individuals (ClinVar; Khan, M. et al . (2013)). (P) 1002 - Moderate functional evidence supporting abnormal protein function (Dossena, S. et al. (2011); Walsh, T. et al. (2006)). (P) 1208 - Inheritance information for this variant is not currently available. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign
MGZ Medical Genetics Center RCV000169244 SCV002580662 pathogenic Pendred syndrome 2022-01-24 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV001814026 SCV002776735 pathogenic Autosomal recessive nonsyndromic hearing loss 4; Pendred syndrome 2021-12-06 criteria provided, single submitter clinical testing
Al Jalila Children's Genomics Center, Al Jalila Childrens Speciality Hospital RCV000724118 SCV002818283 pathogenic not provided 2022-12-17 criteria provided, single submitter clinical testing
UAEU Genomics Laboratory, United Arab Emirates University RCV001004629 SCV003926556 pathogenic Autosomal recessive nonsyndromic hearing loss 4 2021-11-22 criteria provided, single submitter research The missense variant NM_000441.2(SLC26A4):c.716T>A (p.Val239Asp) has been observed in several individuals and families affected with SLC26A4-related conditions (PMID: 12974744, 16460646, 23770805, 25394566). The Val239Asp is a common variant in the SLC26A4 gene that is associated with Pendred syndrome in the Pakistani population (PMID:19287372). This variant is observed in 51/30616 (0.1666%) alleles from individuals of gnomAD South Asian background in the gnomAD dataset (Genome Aggregation Database et al., 2020), but was not seen in the homozygous state. Computational prediction tools and conservational analysis predict that the p.Val239Asp missense change has a damaging effect on the protein structure or function. Experimental studies have shown that this missense change has a deleterious effect on protein function and localization (PMID: 16460646, 22116360) For these reasons, this variant has been classified as Pathogenic.
Neuberg Supratech Reference Laboratories Pvt Ltd, Neuberg Centre for Genomic Medicine RCV000169244 SCV004048529 pathogenic Pendred syndrome criteria provided, single submitter clinical testing The missense variant c.716T>A (p.Val239Asp) in SLC26A4 gene has been observed in several individuals and families affected with SLC26A4-related conditions (Tekin M et.al.,2003). Experimental evidence reports the variant to lead to improper intracellular localization and retainment in the endoplasmic retuclum, and impaired protein function (Walsh T et.al.,2006). This variant has been reported to the ClinVar database as Pathogenic. The p.Val239Asp variant is novel (not in any individuals) in 1000 Genomes and allele frequency of 0.02028 % is reported in gnomAD. The amino acid Val at position 239 is changed to a Asp changing protein sequence and it might alter its composition and physico-chemical properties. The variant is predicted to be damaging by both SIFT and PolyPhen2. The residue is conserved across species. The amino acid change p.Val239Asp in SLC26A4 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic.
Baylor Genetics RCV001004629 SCV004201823 pathogenic Autosomal recessive nonsyndromic hearing loss 4 2023-10-26 criteria provided, single submitter clinical testing
Neuberg Supratech Reference Laboratories Pvt Ltd, Neuberg Centre for Genomic Medicine RCV001004629 SCV004697373 uncertain significance Autosomal recessive nonsyndromic hearing loss 4 criteria provided, single submitter clinical testing The missense variant c.716T>A (p.Val239Asp) in the SLC26A4 gene has been reported previously in homozygous state in individuals affected with hearing loss. Experimental evidence reports the variant to lead to improper intracellular localization and retainment in the endoplasmic reticulum, and impaired protein function (Walsh et al., 2006; Dossena et al., 2011). This variant is reported with the allele frequency (0.02%) in the gnomAD and novel (not in any individuals) in the 1000 genome database. It is submitted to ClinVar with varying interpretations as Likely Pathogenic/Pathogenic (Multiple submission). The amino acid Valine at position 239 is changed to an Aspartic Acid changing the protein sequence and it might alter its composition and physico-chemical properties. The variant is predicted as damaging by SIFT. The amino acid change p.Val239Asp in SLC26A4 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000036506 SCV000060161 pathogenic Rare genetic deafness 2008-09-19 no assertion criteria provided clinical testing
Hereditary Research Laboratory, Bethlehem University RCV000169244 SCV000538118 pathogenic Pendred syndrome 2016-06-04 no assertion criteria provided research Severe to Profound SNHL
National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center RCV001004629 SCV000994874 affects Autosomal recessive nonsyndromic hearing loss 4 2019-08-20 no assertion criteria provided literature only in vitro experiment
Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City RCV000169244 SCV001133020 likely pathogenic Pendred syndrome 2019-09-26 no assertion criteria provided clinical testing
Natera, Inc. RCV000169244 SCV001455802 pathogenic Pendred syndrome 2020-09-16 no assertion criteria provided clinical testing
University of Washington Center for Mendelian Genomics, University of Washington RCV001291246 SCV001479671 likely pathogenic Hearing loss, autosomal recessive no assertion criteria provided research
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV000724118 SCV001951462 likely pathogenic not provided no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000724118 SCV001969734 pathogenic not provided no assertion criteria provided clinical testing
GeneReviews RCV000169244 SCV001994882 not provided Pendred syndrome no assertion provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.